Fatty liver disease (MASLD/MASH): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PPAR 1
• AMPK 0
• GLP-1 7
• SGLT2 5
• NRF2 1
• SIRT1 0
• PNPLA3 6
• NLRP3 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• TLR4 0
• MAPK 0
• STING 0
• JNK 0
• TP53 0
• PINK1 0
• TNF 2
• HIF-1 0
• JAK 0
• GIP 1
• TFEB 0
• YAP 0
• CTNNB1 0
• ERK 0
• COX-2 0
• HSP90 0
• PTEN 0
• STK11 0
• APOE 0
• FTO 0
• HMGB1 0
• IL-6 0
• KEAP1 0
• PCSK9 0
• DPP-4 0
• GPX4 0
• VEGF 0
• FGFR 0
• IL-17 0
• PDGFR 0
• BDNF 0
• IL-1 0
• METTL3 0
• PKM2 0
• TREM2 0
• ACE2 0
• EGFR 0
• FAK 0
• IDH 0
• IDO1 0
• MDM2 0
• PARP 0
• PD-1 0
• RANKL 1
• ABL1 0
• ALK 0
• BCL-2 0
• CD38 0

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Subcellular Lipid Atlas: Decoding Organelle Identity with Targeted Lipid Profiling (LipID)

  Universitat Wien· Wien, Austria· EU contribution €1,500,000· until Jun 2032· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Metabolic Hepatoprotection to Enable Curative Cancer Therapy in Patients with Vulnerable Livers (SAFE-LIVER)

  Universitaet Bern· Bern, Switzerland· EU contribution €150,000· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Epigenomic Liquid Biopsy for Early Detection and Monitoring of Metabolic Dysfunction-Associated Steatohepatitis (cfChIP-MASH)

  The Hebrew University of Jerusalem· Jerusalem, Israel· EU contribution €150,000· until Jan 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Crossing borders of liver and adipose tissue (mis)communication: a novel translational approach to study molecular mechanisms and targets in metabolic dysfunction-associated steatotic liver disease (XB-LIVAT)

  Fondazione Italiana Fegato E.t.s.· Trieste, Italy· EU contribution €193,643· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploring the impact of Time-Restricted Eating and Exercise interventions on Gut microbiome of patients with hepatic steatosis and obesity – TREEGut

  Universidad de Granada· Granada, Spain· EU contribution €194,075· until Dec 2027· 2 countries

5 of 22 running projects, newest first. Listed amounts together: €71.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

  NCT07740109· Tabriz University of Medical Sciences· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 17
• Mendelian Randomization Analysis 45
• CRISPR-Cas Systems 3
• Gene Expression Profiling 105
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 3
• Exome Sequencing 2
• Proteomics 66
• Metabolomics 104
• Mass Spectrometry 10
• Flow Cytometry 3
• Immunohistochemistry 16
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 103
• Machine Learning 103
• Deep Learning 14
• Cohort Studies 173
• Genome-Wide Association Study 49

• Nε-(Carboxymethyl)lysine induces mitochondrial stress, inflammatory activation, and fibrogenic remodelling in multicellular human liver organoids.

  Pharmacol Res, Sept 2026

• Prime editing models the MTARC1 A165T variant in human liver organoids, demonstrating reduced steatosis, inflammation, and fibrosis.

  Hepatol Commun, Sept 2026

• A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing.

  PLoS One, Aug 2026

• MASH Background Confers Enhanced Disease Susceptibility and Acetaminophen Toxicity in iPSC-Derived Liver Organoids.

  Adv Sci (Weinh), Jul 2026

• Application of Multilineage Human Liver Organoids in Disease Modelling, Drug Testing and Genetic Intervention.

  Liver Int, Jul 2026

• Hepatoprotective effects of the branched-chain fatty acids 12-methylmyristic and 13-methylmyristic against palmitate-induced lipotoxicity.

  Biomed Pharmacother, Jun 2026

• S100A10-ANXA2 tetramer inhibition hampers hepatic stellate cell activation in human MASLD organoids.

  EMBO Mol Med, Jun 2026

• Profiling of extracellular vesicles from primary hepatocytes, organoids, and mash patients identifies cell injury-specific signatures.

  Sci Rep, Jun 2026

• Organoid models reveal mechanistic connections and sirolimus efficacy in liver-vascular steatosis and foam cell formation.

  Atherosclerosis, May 2026

• New approach methodologies to model liver fibrosis in metabolic dysfunction-associated steatohepatitis.

  BMB Rep, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.